|
Free Research Articles
Citations 251-260 of 789 total displayed.
|
Past content
(since May 2004):
|
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
- David Marin, Dragana Milojkovic, Eduardo Olavarria, Jamshid S. Khorashad, Hugues de Lavallade, Alistair G. Reid, Letizia Foroni, Katayoun Rezvani, Marco Bua, Francesco Dazzi, Jiri Pavlu, Matthias Klammer, Jaspal S. Kaeda, John M. Goldman, and Jane F. Apperley
Blood 2008; 112: 4437-4444.
[Abstract]
[Full text]
[PDF]
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
- Michael Wang, Meletios A. Dimopoulos, Christine Chen, M. Teresa Cibeira, Michel Attal, Andrew Spencer, S. Vincent Rajkumar, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert D. Knight, and Donna M. Weber
Blood 2008; 112: 4445-4451.
[Abstract]
[Full text]
[PDF]
Thalidomide and rituximab in Waldenstrom macroglobulinemia
- Steven P. Treon, Jacob D. Soumerai, Andrew R. Branagan, Zachary R. Hunter, Christopher J. Patterson, Leukothea Ioakimidis, Frederick M. Briccetti, Mark Pasmantier, Harvey Zimbler, Robert B. Cooper, Maria Moore, John Hill, II, Alan Rauch, Lawrence Garbo, Luis Chu, Cynthia Chua, Stephen H. Nantel, David R. Lovett, Hans Boedeker, Henry Sonneborn, John Howard, Paul Musto, Bryan T. Ciccarelli, Evdoxia Hatjiharissi, and Kenneth C. Anderson
Blood 2008; 112: 4452-4457.
[Abstract]
[Full text]
[PDF]
Hemoglobin research and the origins of molecular medicine
- Alan N. Schechter
Blood 2008; 112: 3927-3938.
[Abstract]
[Full text]
[PDF]
Red cell membrane: past, present, and future
- Narla Mohandas and Patrick G. Gallagher
Blood 2008; 112: 3939-3948.
[Abstract]
[Full text]
[PDF]
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
- Timothy P. Hughes, Susan Branford, Deborah L. White, John Reynolds, Rachel Koelmeyer, John F. Seymour, Kerry Taylor, Chris Arthur, Anthony Schwarer, James Morton, Julian Cooney, Michael F. Leahy, Philip Rowlings, John Catalano, Mark Hertzberg, Robin Filshie, Anthony K. Mills, Keith Fay, Simon Durrant, Henry Januszewicz, David Joske, Craig Underhill, Scott Dunkley, Kevin Lynch, and Andrew Grigg, on behalf of the Australasian Leukaemia and Lymphoma Group
Blood 2008; 112: 3965-3973.
[Abstract]
[Full text]
[PDF]
Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura
- Cindy E. Neunert, George R. Buchanan, Paul Imbach, Paula H. B. Bolton-Maggs, Carolyn M. Bennett, Ellis J. Neufeld, Sara K. Vesely, Leah Adix, Victor S. Blanchette, and Thomas Kühne, for the Intercontinental Childhood ITP Study Group Registry II Participants
Blood 2008; 112: 4003-4008.
[Abstract]
[Full text]
[PDF]
Immunoassay for human serum hepcidin
- Tomas Ganz, Gordana Olbina, Domenico Girelli, Elizabeta Nemeth, and Mark Westerman
Blood 2008; 112: 4292-4297.
[Abstract]
[Full text]
[PDF]
The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases
- Irving L. Weissman and Judith A. Shizuru
Blood 2008; 112: 3543-3553.
[Abstract]
[Full text]
[PDF]
Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment
- Guido Stoll, Christoph Kleinschnitz, and Bernhard Nieswandt
Blood 2008; 112: 3555-3562.
[Abstract]
[Full text]
[PDF]
|
|
